Ansari Hossein, Kouti Leila
Department of Neurology, University of California San Diego (UCSD), La Jolla, CA, USA.
School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Curr Pain Headache Rep. 2016 Aug;20(8):50. doi: 10.1007/s11916-016-0579-3.
Treatment of headache, specifically migraine attacks, has always been a challenging subject, especially for neurologist and pain specialists. Triptans are generally underutilized, despite being the gold standard abortive medication for migraine attacks. On the other hand, opioid analgesics are overused as a treatment for headache. One reason for this could be physician unfamiliarity with drug interactions between opioids and other medications, especially the possibility of serotonin toxicity. The general awareness of potential serotonin toxicity with using opioid analgesics is low. In this review, we will conduct a theoretic and evidence-based review of the potential for developing serotonin syndrome in patients who are using opioids analgesics, especially in combination with antidepressants, a common co-prescribed combination. We also review the current diagnostic criteria for serotonin syndrome and identify possible shortcomings of those criteria. Our aim is to increase the awareness of health care providers about potential drug interaction of opioid analgesics with other classes of medication. We place particular emphasis on tramadol since this drug is one of the most commonly used opioid analgesics for headache. The potential for developing serotonin syndrome is relatively high in the patients who are using opioid for pain control. The use of opioids in migraine headache is already discouraged due to the high risk of medication overuse headache and also an increase in headache-related disability (Katsarava et al. Neurology 62:788-790, 2004; Bigal and Lipton. Neurology 71:1821-8, 2008; Casucci and Cevoli. Neurol Sci. 34 Suppl 1:S125-8, 2013). This is another reason that physicians and health care providers should avoid using this class of medication for pain, specifically headache and migraine treatment.
头痛的治疗,尤其是偏头痛发作的治疗,一直是一个具有挑战性的课题,对于神经科医生和疼痛专家来说尤其如此。尽管曲坦类药物是偏头痛发作的金标准终止发作药物,但它们的使用普遍不足。另一方面,阿片类镇痛药被过度用作头痛的治疗药物。造成这种情况的一个原因可能是医生对阿片类药物与其他药物之间的药物相互作用不熟悉,尤其是血清素毒性的可能性。使用阿片类镇痛药时潜在血清素毒性的总体认识较低。在本综述中,我们将对使用阿片类镇痛药的患者,尤其是与抗抑郁药联合使用(一种常见的联合处方组合)时发生血清素综合征的可能性进行理论和基于证据的综述。我们还将回顾血清素综合征的当前诊断标准,并确定这些标准可能存在的缺陷。我们的目的是提高医疗保健提供者对阿片类镇痛药与其他药物类别之间潜在药物相互作用的认识。我们特别强调曲马多,因为这种药物是治疗头痛最常用的阿片类镇痛药之一。在使用阿片类药物控制疼痛的患者中,发生血清素综合征的可能性相对较高。由于药物过度使用性头痛的高风险以及头痛相关残疾的增加,偏头痛头痛患者已经不鼓励使用阿片类药物(卡萨拉瓦等人,《神经病学》62:788 - 790,2004;比加尔和利普顿,《神经病学》71:1821 - 8,2008;卡苏奇和切沃利,《神经科学杂志》34增刊1:S125 - 8,2013)。这是医生和医疗保健提供者应避免使用这类药物治疗疼痛,特别是头痛和偏头痛的另一个原因。